

## Prevalence of Glucose-6-Phosphate Dehydrogenase and Thyroid Hormones Deficiency in Neonatal Jaundice

<sup>1</sup>Wael R Hablas , <sup>2</sup>Salwa K El- Nabarawy <sup>2</sup>Nadia F Ibrahim and <sup>3</sup>Noha M Radwan

<sup>1</sup> Clinical Pathology Department, Faculty of Medicine, Al Azhar University (Boys Branch) ,

<sup>2</sup>Zoology Department Faculty of Science Al Azhar University ( Girls Branch) and <sup>3</sup> Nile Company for Pharmaceutical & Chemical industries, Research & Control Sector.

### Abstract

G6PD deficiency is the most common inherited metabolic disorder and clinically significant red cell enzyme defect in man. Severe neonatal jaundice proved to be the most common clinical manifestation and a globally important most dangerous consequence of G6PD deficiency. Prolonged jaundice is sometimes associated with congenital hypothyroidism. So the early characterization of G6PD activity and thyroid hormone levels provides an etiological diagnosis for neonatal jaundice as well as the opportunity to give the newborn's family information concerning hemolytic crisis prevention and an early management in case of hypothyroidism.

**Aim:** This study was conducted in an attempt to evaluate the prevalence of G6PD deficiency and hypothyroidism in relation to neonatal physiological hyperbilirubinemia.

**Subjects and Methods:** The study included 50 neonates aged between 6 hr – 5 days, forty infants had jaundice and the other ten (control), were healthy neonates, matching the same age. All infants of the study were subjected to C-RP test, routine hematological evaluation, and serum total bilirubin levels, quantitative red blood cells G6PD assay and thyroid hormone levels.

**Results:** All the fifty cases of both jaundiced and healthy neonates were negative for C-RP test indicating that the 40 cases had physiological jaundice. The study revealed that G6PD enzyme was lower than normal level in 2 cases (5%). TSH level was found to be higher than normal in 13 jaundiced neonates out of 40 (33%). Seven jaundiced neonates (18%) had T<sub>4</sub> hormone lower than normal while all the 40 jaundiced cases had normal T<sub>3</sub> level. Correlation of the total bilirubin was significant with TSH and T<sub>3</sub> at 0.05 levels, while there was no significance with both T<sub>4</sub> and G6PD.

**Conclusion:** statistically there was no correlation between bilirubin and both G6PD enzyme and thyroid hormones, but the incidence of hypothyroidism in this study was high (18%) and the incidence of G6PD deficiency was (5%). This indicates a role of G6PD deficiency and hypothyroidism in developing neonatal jaundice among neonates. So, early neonatal screening program is recommended for early management.

**Key words:** Neonatal jaundice, G6PD deficiency, Thyroid hormones.

### Introduction

Early-onset hyperbilirubinaemia is a high-risk condition because it often presents with an acute and rapid rise in bilirubin values. Although the outcome for most is benign, infants with extremely high serum bilirubin can develop acute bilirubin encephalopathy in the absence of urgent intervention <sup>(1)</sup> depending on the permeability of the blood brain barrier to bilirubin or albumin <sup>(2)</sup>. Neonatal hyperbilirubinemia, (defined as a serum total bilirubin level exceeding 5 mg/dl) is a frequent problem <sup>(3)</sup>. Neonatal jaundice affects 60% of full-term infants and 80% of preterm infants in the first three days of life. Although transient, the condition accounts for up to 75% of hospital readmissions in the first week after birth <sup>(4)</sup> and it

is a common reason for neonates to present in the emergency department <sup>(5)</sup>.

Hyperbilirubinemia is caused both by increased production of bilirubin as the heme in red blood cells is broken down and by decreased bilirubin excretion due to inadequate hepatic conjugation and increased enterohepatic reabsorption <sup>(6)</sup>.

Although physiological jaundice is more frequent as compared to pathological jaundice, it is very important to differentiate between the two, as pathological jaundice may lead to kernicterus and subsequently brain damage. Treatment is dependent upon the amount of serum bilirubin and various other laboratory investigations. Thus laboratory workup is very

important for diagnosis and prevention of neonatal hyperbilirubinemia in newborn <sup>(7)</sup>.

Causes of pathological jaundice are hemolysis, breast feeding, infections, hypothyroidism and extrahepatic biliary atresia and needs investigation and medical intervention <sup>(8)</sup>.

Glucose-6-phosphate dehydrogenase is an x-linked recessive disease, where the deficiency of the enzyme causes a spectrum of clinical manifestations ranging from neonatal jaundice to chronic non-spherocytic anemia, to infection and drug-induced hemolysis <sup>(9)</sup>.

Hypothyroidism is the disease state caused by insufficient production of thyroid hormones by the thyroid gland. Thyroid hormones are essential for normal organ growth, development and function. The major secretory product of the thyroid is a prohormone (T<sub>4</sub>), which is activated in peripheral tissues by outer ring deiodination to T<sub>3</sub> <sup>(10)</sup>. Prolonged jaundice is sometimes associated with congenital hypothyroidism which appears to be associated with the delayed maturation of hepatic uridine diphosphate glucuronyl transferase enzyme activity <sup>(11)</sup>.

#### Aim of the work

The aim of this work was to make an early detection of G6PD deficiency and hypothyroidism in neonates suffering from postnatal physiological jaundice in order to start early management.

#### Material and Methods

Fifty Egyptian neonates (6 hrs - 5 days) were chosen for this study after agreement of their families. Forty jaundiced infants were selected from the **Neonatal Care Unit of Tabarak Hospital**. They were treated only with phototherapy and there was no need for blood transfusion. Other ten healthy infants matching the same age were taken as control. All of the neonates were full-term, with good weight for the gestational age and no malformations.

Blood samples were collected from jaundiced and healthy neonates and each sample was divided into two parts: One part was used to separate serum to estimate C-Reactive protein (C-RP)<sup>(12)</sup>, total bilirubin <sup>(13)</sup> and thyroid hormones; TSH <sup>(14)</sup>, T<sub>4</sub> and T<sub>3</sub> <sup>(15)</sup>. The other part was added to an anticoagulant (heparin) to be used within 3 hours to estimate G6PD enzyme activity <sup>(16)</sup> and complete blood picture (WBCs, RBCs, platelets, reticulocytes, and total counts; hematocrit <sup>(17)</sup> and hemoglobin concentrations <sup>(18)</sup>.

Calculation of MCH, MCV and MCHC was carried out.

#### Statistical Analysis:

SPSS for windows version 17.0 and Excel computer programs were used for statistical analysis. Descriptive, t test, correlation and percentage analysis were made. Pearson Correlation was significant at p 0.05 and high significant at p 0.01 levels.

#### Results

All the fifty cases of both jaundiced and healthy neonates were negative in the C-Reactive protein.

Figure (1) shows the mean (14.39 mg/dl) concentration of serum total bilirubin in jaundiced neonates group in comparison to the mean (2.28 mg/dl) value in healthy neonates. Table (1) shows the normal, low and high numbers and calculated percentage values (%) for each of serum total bilirubin, G6PD, TSH, T<sub>4</sub> and T<sub>3</sub> in the hyperbilirubinemic neonates group. Table (2) shows that the correlation of total bilirubin with TSH and T<sub>3</sub> was significant at 0.05 level, while there was no significant difference with both T<sub>4</sub> and G6PD.

The mean level of G6PD enzyme activity was 14.93 U/gHb while in healthy neonates group it was 11.06 U/gHb as presented in figure (2). Table (1) also showed that 20 cases of the jaundiced neonates group, (50%) had normal G6PD activity, 18 cases (45%) had enzyme activity higher than normal and only 2 cases (5%) had G6PD deficiency. As shown in table (3) the two G6PD deficient infants enzyme activity was 1.6 and 4.0 U/gHb. The total WBCs count of the two cases was lower than normal level. On the other hand, hemoglobin (19.5 g/dl and 20.4 g/dl), hematocrite (80% and 60%) and reticulocytes (4% and 3%) were high compared to normal values. TSH, T<sub>4</sub>, T<sub>3</sub>, platelets, RBCs, MCH, MCV and MCHC were within the normal values as presented in table (3). Correlation of G6PD was significant with both TSH and T<sub>4</sub> at (0.01) level, but not significant with T<sub>3</sub> (Table 2).

Data presented in figure (3) showed the mean level of TSH in hyperbilirubinemic and healthy neonates groups (10.47 U/Iu ml) and (3.19 U/Iu ml respectively). In the jaundiced neonates group, TSH of 13 cases (33%) was higher than normal level, while 27 cases (67%) had normal hormone level as presented in table (1).

Correlation of TSH with both T<sub>4</sub> and T<sub>3</sub> was highly significant at 0.01 levels (Table 2).

The mean concentration of T<sub>4</sub> was 9.19 ng/dl in hyperbilirubinemic neonates group compared to 11.13 ng/dl in the healthy neonates as presented in figure (4). In the jaundiced neonates group, 30 cases (75%) had normal hormone level, 7 cases (18%) were lower than normal level and 3 cases (7%) were higher than normal level as presented in table (1). Of the seven cases with low T<sub>4</sub>, six had high TSH level while the 7<sup>th</sup> case was within normal value. All parameters of the seven cases are shown in table (4). Correlation of T<sub>4</sub> with T<sub>3</sub> was not significant as shown in table (2).

Furthermore figure (5) shows pronounced elevation in T<sub>3</sub> level (151.14 ng/dl) of hyperbilirubinemic group compared to the healthy neonates mean value (94.2 ng/dl). All the 40 jaundiced neonates had normal T<sub>3</sub> level as presented in table (1).

As demonstrated in figure (6), total WBCs count mean value in hyperbilirubinemic group was  $86.3 \times 10^2$  cells/mm<sup>3</sup> while in healthy neonates it was  $86.80 \times 10^2$  cells/mm<sup>3</sup> and the mean count of RBCs in jaundiced neonates was  $505 \times 10^4$  cells/mm<sup>3</sup> while it was  $494 \times 10^4$  cells/mm<sup>3</sup> in control group (figure 7). Meanwhile, platelets count mean value was decreased ( $255.50 \times 10^3$  cells/mm<sup>3</sup>) in hyperbilirubinemic group compared to healthy neonates group (Figure 7). Reticulocytes mean value in jaundiced neonates was much higher (7.45%) than that in healthy neonates group (1.1%) and it is presented in fig. (8) which also shows results of hematocrit mean that was slightly elevated (50.08%) in jaundiced neonates in comparison with that of control (48.0%). Moreover, hemoglobin mean concentration level in jaundiced neonates was 16.39 gm/dl while it was 15.74 gm/dl in healthy neonates (Fig.9). The mean calculated values of MCH, MCV and MCHC in hyperbilirubinemic group as well as that in control group are shown in figure (10).

## Discussion

Neonatal hyperbilirubinaemia is a common finding during the first postnatal week. Physiological jaundice occurs in first week of life in 60% of term and 80% of premature neonates. On the other hand, non physiologic or pathologic jaundice occurs in 5-10% of newborns which require intervention (19).

It is well recognized that in G6PD deficiency, early destruction of RBCs under oxidative stress causes release of hemoglobin, which is

subsequently metabolized to form bilirubin that leads to the development of hyperbilirubinemia of neonates (20, 21). Hypothyroidism is the most common disorder arising from hormone deficiency (22). Thyroxin (T<sub>4</sub>) which is the main product of the thyroid and circulates in plasma is converted to T<sub>3</sub>. T<sub>4</sub>, in many respects, is considered as a prohormone for the more potent T<sub>3</sub> (23).

In the present study: All the investigated parameters in healthy neonates were within the normal range. Reticulocytes in jaundiced neonates was higher than the normal values and this could explain the high mean value of G6PD enzyme because in normal blood, reticulocytes have about five times more activity than the oldest erythrocyte subpopulation (24-26).

In the present study: G6PD percentage showed that only 5% (2 infants out of the forty hyperbilirubinemic neonates) were deficient in G6PD enzyme activity. Also the two cases were with normal levels of thyroid hormones and normal RBCs count. Incidence of G6PD deficiency in this study was in accordance with the finding of a study made on 2501 newborns and the overall incidence of G6PD deficiency was 3.2% (27). Another study revealed that from 272 neonates 12 babies (4.4%) were found to have G6PD deficiency (28).

The current study revealed that, statistically, there was no correlation between bilirubin and G6PD enzyme. However, many studies showed significant correlation between G6PD deficiency and neonatal jaundice. Also those studies revealed that the severity of hyperbilirubinemia depends on degree of G6PD deficiency and that its prevalence in severe hyperbilirubinemia is more than moderate hyperbilirubinemia (29, 30).

Other studies agreed with the present study in that there is no statistical correlation between G6PD and jaundice and that jaundice is associated with normal and G6PD deficient status (31). Also, another study suggested that hemolysis is only partly responsible of jaundice and that decreased bilirubin conjugation and elimination play a major role in the pathogenesis of neonatal jaundice (32).

In the current study, G6PD was directly proportional with TSH and inversely proportional with T<sub>4</sub>. Earlier studies have shown that thyroid hormones do influence the levels of G6PD in the erythrocytes (33, 34). In addition, many studies found that the levels and activity of the enzyme decreased in hyperthyroid and increased in hypothyroid patients (35-37).

Of the 40 neonates, 7 cases (18%) had  $T_4$  values lower than normal. Of the seven neonates with low  $T_4$  six were with high TSH which indicated that they have hypothyroidism and the 7<sup>th</sup> neonate was with normal TSH and should make free  $T_4$  hormone to ensure that he had hypothyroidism. The 7 neonates were with normal G6PD value but two of them had low RBCs count. Primary congenital hypothyroidism has a birth prevalence of 1:2750<sup>(38)</sup> to 1:4000 newborns<sup>(39)</sup> but in jaundiced neonates ratio raises to 10%<sup>(40)</sup>.

In this study, bilirubin showed no statistical significant correlation with  $T_4$ , but it was directly proportional to  $T_3$ . TSH result was similar to that of a study carried by<sup>(41)</sup> who recorded that total bilirubin values decreased as TSH increases. Bilirubin is increased in serum of critically-ill patients and was suggested as one of the factors causing the low  $T_3$  plasma concentrations in these patients, by the inhibition of  $T_4$  transport into the liver<sup>(42)</sup>. The decrease of thyroid hormones in case of hyperbilirubinemia is due to alterations of thyroid hormone metabolism in cases of unconjugated hyperbilirubinemia. These effects might involve inhibition of thyroid hormone uptake by their target cells<sup>(43)</sup>. On the other hand, other studies revealed that neither bilirubin nor biliverdin affected uptake of  $T_3$  or  $T_4$ <sup>(44)</sup>.

The present study demonstrated that TSH was inversely proportional with both  $T_3$  and  $T_4$  that represented the classic negative feedback mechanism of the thyroid axis<sup>(45,46)</sup>.

The goal of newborn screening is the pre-symptomatic detection of infants with congenital conditions so that treatment may be commenced as early as possible to prevent, or ameliorate, the long-term consequences of the condition<sup>(47)</sup>.

An Egyptian study made by **El-Menshay et al.**<sup>(48)</sup> concluded that the incidence of G6PD deficiency in jaundiced infants was high and signifies the role of G6PD deficiency in developing neonatal jaundice among Egyptian infants. So early screening programs should be instituted in countries where the deficiency is prevalent. Also **Abdel Fattah et al.**<sup>(49)</sup> concluded that G6PD deficiency is an important cause for neonatal jaundice in Egyptians and neonatal screening for its deficiency is recommended.

Newborn screening for congenital hypothyroidism followed by the early initiation of thyroid hormone treatment to normalize thyroxin ( $T_4$ ) concentrations has been shown to prevent intellectual disability i.e., mental

retardation<sup>(50)</sup>. Hypothyroidism after the age of three years, when most of the thyroid hormone-dependent brain development is complete, results in slow growth and delayed skeletal maturation<sup>(51)</sup>.

## References

- Huang A, Choo BT, Ying LW, Lee J and Leong EY (2009):** Differential risk for early breastfeeding jaundice in multi-ethnic Asian cohort. *Annals Academy of Medicine*, 38(3): 217-224.
- Lee C, Lee SM and Namgung R (2013):** Bilirubin Metabolism and Bilirubin Encephalopathy. *Neonatal Med.*, 20(3): 268-275.
- Dennis BLPML (2002):** Hyperbilirubinemia in the term newborn. *Am Fam Physician*, 65: 599-606.
- Koosha A and Rafizadeh B (2007):** Evaluation of neonatal indirect hyperbilirubinaemia at Zanjan Province of Iran in 2001- 2003: prevalence of glucose-6-phosphate dehydrogenase deficiency. *Singapore Med J.*, 48(5):424-428.
- Wolff M, Schinasi DA, Lavelle J, Boorstein N and Zorc JJ (2012):** Management of Neonates With Hyperbilirubinemia: Improving Timeliness of Care Using a Clinical Pathway. *Pediatrics*, 130(6): e1688-e1694.
- Burgos AE, Flaherman VJ and Newman TB (2012):** Screening and follow up for neonatal hyperbilirubinemia: A Review. *Clinical pediatrics*, 51(1): 7-16.
- Shah A, Shah CK and Shah V (2012):** Study of hematological parameters among neonates admitted with neonatal jaundice. *Journal of Evolution of Medical and Dental Sciences*, 1(3): 203.
- Singh K, Borrison A and Mahdi AA (2014):** Concept of BuBc in neonatal jaundice: needs a change. *Journal of Pediatric Sciences*, 6:e203.
- Atay, E.; Bozaykut, A. and Ozahi I.I (2005):** Glucose-6-phosphate dehydrogenase deficiency in neonatal indirect hyperbilirubinemia. *Journal of Tropical Pediatrics*, 52(1): 56-58.
- Yadav A, Arora S, Saini V, Arora MK, Singh R and Bhattacharjee J (2013):** Influence of thyroid hormones on biochemical parameters of liver function: a case-control study in North Indian population *Internet Journal of Medical Update*, 8(1): 4-8.
- Singh B, Ezhilarosan R, Kumar P and Narang A (2003):** Neonatal hyperbilirubinemia and its association with thyroid hormone levels & urinary iodine excretion. *Indian Journal of Pediatrics*, 70(4): 311-315.
- Fischel EE and Cohen AA (1967):** Laboratory diagnostic procedures in rheumatic disease. Little Brown & C. Boston, P.70.
- Jendrassik L and Grof P (1938):** Vereinfachte photometrische methoden zur bestimmung des bilirubins. *Biochem Z.*, 297: 81- 89.

- 14.National Committee for Clinical Laboratory Standards (1997):** Reference method for both dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National committee for clinical laboratory standards, Wayne, Pa.
- 15.Tietz NW (1995):** Clinical guide to laboratory tests. 3<sup>rd</sup> ed. Philadelphia. WB Saunders, ISBN 0-7216-5035-x.
- 16.Tietz NW (1986):** Clinical chemistry. Philadelphia Saunders, 2<sup>nd</sup> ed.: 1501- 1502.
- 17.Dacie JV and Lewis SM (2001):** In "Practical hematology" 10<sup>th</sup> ed. Longman, group U.K.
- 18.International Committee for Standardization in Hematology(1967):** Birt J Hemat., 13(Suppl.) 71.
- 19.Afzal N, Qadir M, Qureshi S, Ali R, Ahmed S and Ahmad K (2012):** Urinary tract infection presenting as jaundice in neonates. J Pak Med Assoc., 62(7): 735-737.
- 20.Smith JC (2005):** Disorders of red cell metabolism. In: Hoffbrand AV, Oatovsky D, Tuddenham ED. Postgraduate hematology. Oxford: Blackwell publishing Ltd.
- 21.Salamatu J, Rostenberghe HV, Yusoff MN, Ghazali S, Ismail NZN, Matsuo M, Wahab AN and Nishio H (2005):** In glucose-6-phosphate dehydrogenase-deficient babies. Pediatr Int., 47: 258-261.
- 22.Athanassiou IK and Ntalles K (2010):** Hypothyroidism - neaspects of an old disease. Hippokratia, 14(2): 82-87.
- 23.Bianco AC, Salvatore D, Gereben B, Berry MJ and Larsen PR (2002):** Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev., 23: 38-89.
- 24.Suzuki T and Dale GL (1988):** Senescent erythrocytes: Isolation of in vivo aged cells and their biochemical characteristics. Proc Natl Acad Sci USA., 85: 1647.
- 25.Zimran A, Forman L, Suzuki T, Dale GL and Beutler E (1990):** In vivo aging of red cell enzymes: Study of biotinylated red blood cells in rabbits. Am J Hematol., 33: 249.
- 26.Prchal JT and Gregg XT (2005):** Deficiency as protection against falciparum malaria: An epidemiological critique of population and experimental studies. Yearbook of Phys Anthropol., 36: 153-178.
- 27.Iranpour R, Hashemipour M, Talaei SM, Soroshnia M and Amini A (2008):** Newborn screening for glucose-6-phosphate dehydrogenase deficiency in Isfahan, Iran: a quantitative assay. Journal of medical screening, 15(2): 62-64.
- 28.Eghbalian E and Monsef AR (2007):** Evaluation of glucose-6-phosphate dehydrogenase deficiency without hemolysis in icteric newborns. Iranian journal of pediatrics, 17(1): 36-40.
- 29.Ardhakani SB, Nikkhah A and Sedaghat M (2007):** The association between G6PD deficiency and total serum bilirubin level in icteric neonates. Acta Medica Iranica, 45(3): 233-235.
- 30.Akhter N, Begum N and Khan WA (2009):** Glucose-6-phosphate dehydrogenase status in neonatal jaundice and its relationship with severity of hyperbilirubinemia. J Bangladesh Soc Physiol., 4(2): 71-76.
- 31.Tan KL (1981):** Glucose-6-phosphate dehydrogenase status and neonatal jaundice. Arch Dis Child, 67(11): 874-877.
- 32.Kaplan M, Rubaltelli FF, Hammerman C, Vilei MT, Leiter C, Abramov A and Muraca M (1996):** Conjugated bilirubin in neonates with glucose-6-phosphate dehydrogenase deficiency. J Pediatr., 128: 695-697.
- 33.Nehal M and Baquer NZ (1989):** Changes in hexokinase and glucose-6-phosphate dehydrogenase in red cells during hypo and hyperthyroidism. Biochem Int., 19: 193-199.
- 34.Lombardi A, Beneduce L, Moreno M, Diano S, Colantuoni V and Ursini MV (2000):** 3,5-diiodo-L-thyronine regulates glucose-6-phosphate dehydrogenase activity in the rat. Endocrinology, 141: 1729-1734.
- 35.Dasmahapatra A, Cohen MP, Grossman SD and Lasker N (1985):** Erythrocyte sodium/potassium adenosine triphosphatase in thyroid disease and nonthyroidal illness. J Clin Endocrinol Metab., 61: 110-115.
- 36.Ogasawara H and Nishikawa M (1988):** Clinical studies on assay for Na-K ATPase in human blood cells. I. Erythrocyte Na-K ATPase assay in patients with thyroid dysfunction and in those with chronic renal failure. Nippon Naibunpi Gakkai Zasshi, 64: 329-339.
- 37.Riva C and Vircici F (1998):** Impaired Na<sup>+</sup>, K<sup>+</sup> ATPase activity in red blood cells in euthyroid women treated with levothyroxine after total thyroidectomy for Graves' disease. Metabolism, 47: 1194-1198.
- 38.Wilcken B and Wiley V (2008):** Newborn screening. Pathology, 40: 104-115.
- 39.Rastogi MV and La Franchi SH (2010):** Congenital hypothyroidism. Orphan journal of rare diseases, 5: 17.
- 40.MacMahan JR, Stevenson DK and Oski FA (2000):** Unconjugated hyperbilirubinemia. In: Taeusch HW, Ballard RA (Eds). Avery's diseases of the newborn. 7<sup>th</sup> edition. Philadelphia: Saunders: 1014-1029.
- 41.Kayiran SM and Gurkan B (2010):** Correlation of third day TSH and thyroxine values with bilirubin levels detected by a neonatal screening system, Medical journal of Bakirkoy, 6(3): 117-120.
- 42.Lim CF, Docter R, Visser TJ, Krenning EP, Bernard B, Van TH, De Jong M and Hennemann G (1993):** Inhibition of thyroxine transport into cultured rat hepatocytes by serum of non-uremic critically- ill patients, bilirubin and non-estrified fatty

acids. *Journal of clinical endocrinology and metabolism*, 76: 1165-1172.

**43.Chantoux F, Chuniad L, Dessante M, Trivin F, Blondeau JP and Francon J (1993):** Competitive inhibition of thyroid hormone uptake into cultured rat brain astrocytes by bilirubin and bilirubin conjugates. *Molecular and cellular endocrinology*, 97 (1-2): 145-151.

**44.Wassen FW, Moerings EP, Toor HV, Hennemann G and Everts ME (2000):** Thyroid hormone uptake in cultured rat anterior pituitary cells: effects of energy status and bilirubin, *Journal of endocrinology*, 165: 599-606.

**45.Haasteren GA, Linkels E, Klootwijk W, Toor H, Rondeel JM, Themmen AP, Jong FH, Valentijn K, Vaudry H and Bauer K (1995):** Starvation-induced changes in the hypothalamic content of prothyrotrophin-releasing hormone (proTRH) mRNA and the hypothalamic release of proTRH-derived peptides: role of the adrenal gland. *J Endocrinol.*, 145(1): 143-153.

**46.Coppola A and Diano S (2007):** Hormonal regulation of the arcuate nucleus melanocortin system. *Frontiers in bioscience*, 12: 3519-3530.

**47.Pitt JJ (2010):** Newborn screening. *Clin Biochem Rev.*, 31: 57-68.

**48.El-Menshay AA, Khalife NM, Awad SA, Fathy MA and Amer AK (2009):** Prevalence of glucose-6-phosphate dehydrogenase deficiency in jaundiced neonates in Egypt. *Australian journal of basic and applied science*, 3(3): 2016-2023.

**49.Abel Fattah M, Abdel Ghany E, Adel A, Mosallam D and Kamal S (2010):** Glucose-6-phosphate dehydrogenase and red cell pyruvate kinase in neonatal jaundice cases in Egypt. *Pediatric hematology-oncology*, 27(4): 262-271.

**50.Asulaimani AA, Almalki M, Alswat H and Osman A (2011):** Monitoring of screening program for neonatal congenital hypothyroidism in Taif governorate (KSA). *Med. J. Cairo Univ.*, 79(2): 17-21.

**51.Desai MP (2011):** Thyroid Function in Children. *Supplement to Japi.*, 59: 35.

**Table (1):** Normal, low and high number and calculated percentage (%) for G6PD activity, TSH, T<sub>4</sub> and T<sub>3</sub> levels in hyperbilirubinemic neonates group.

Parameters \ No. & Percent.	Normal	Low	High
Total Bilirubin	----	----	40(100%)
G6PD	20(50%)	2(5%)	18(45%)
TSH	27(67%)	----	13(33%)
T <sub>4</sub>	30(75%)	7(18%)	3(7%)
T <sub>3</sub>	40(100%)	----	----

**Table (2):** Correlation between bilirubin content, G6PD activity, TSH, T<sub>4</sub> and T<sub>3</sub> levels in hyperbilirubinemic neonates group.

Parameters		Bilirubin	G6PD	TSH	T <sub>4</sub>
G6PD	Pearson Correlation	0.054	----	----	----
	Sig. (2-tailed)	0.741	----	----	----
TSH	Pearson Correlation	-0.323-*	0.438**	----	----
	Sig. (2-tailed)	0.042	0.005	----	----
T <sub>4</sub>	Pearson Correlation	0.075	-0.439-**	-0.581-**	----
	Sig. (2-tailed)	0.644	0.005	0.000	----
T <sub>3</sub>	Pearson Correlation	0.362*	-0.252-	-0.643-**	0.188
	Sig. (2-tailed)	0.022	0.117	0.000	0.245

\* Correlation is significant at the (0.05) level.


\*\*Correlation is highly significant at the (0.01) level.

**Table (3):** Parameter results of the two cases with G6PD deficiency in the hyperbilirubinemic group.


Parameters \ Cases	Case 1	Case 2	Healthy Neonates
Age (days)	2.00	3.50	3.00
G6PD U/g Hb	1.60	4.00	11.06
TSH U Iu/ml	5.90	5.20	3.19
T <sub>4</sub> ng/dl	7.70	10.20	11.13
T <sub>3</sub> ng/dl	180.00	185.0	94.2
WBCs( $\times 10^2$ )cells/mm <sup>3</sup>	52.00	82.00	86.80
RBCs( $\times 10^4$ ) cells/mm <sup>3</sup>	598.0	618.0	494.0
Platelets( $\times 10^3$ )cells/mm <sup>3</sup>	200.0	200.0	320.7
Reticulocytes (%)	4.00	3.00	1.1
Hematocrit (%)	80.00	60.00	48.00
Hemoglobin g/dl	19.50	20.40	15.74
MCH	32.00	33.00	32.62
MCV	100.00	97.00	86.8
MCHC	32.00	34.00	34.3

**Table (4):** Parameter results of the seven cases with T<sub>4</sub> deficiency in the hyperbilirubinemic group.

Parameters	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7	Healthy Neonates
<b>Cases</b>								
Age (days)	1.00	1.00	6 hrs	2.00	3.00	1.50	2.00	3.00
G6PD U/g Hb	10.40	19.80	25.00	22.00	25.00	12.20	18.00	11.06
TSH U Iu/ml	50.00	24.80	40.30	16.10	49.80	32.10	2.60	3.19
T <sub>4</sub> ng/dl	5.10	6.60	5.900	5.40	4.90	6.50	6.40	11.13
T <sub>3</sub> ng/dl	62.00	102.0	91.00	118.0	82.00	118.0	139.0	94.2
WBCs(×10 <sup>2</sup> )cells/m <sup>3</sup>	118.0	106.0	126.0	82.00	64.00	142.0	107.0	86.80
RBCs(×10 <sup>4</sup> )cells/mm <sup>3</sup>	484.0	312.0	374.0	562.0	448.0	392.0	658.0	494.0
Platelets(×10 <sup>3</sup> )cells/mm <sup>3</sup>	260.0	280.0	200.0	200.0	220.0	200.0	220.0	320.7
Reticulocytes (%)	9.00	12.00	14.00	5.00	8.00	7.00	11.00	1.1
Hematocrit (%)	48.00	33.00	40.00	55.00	44.00	38.00	70.00	48.0
Hemoglobin g/dl	15.50	11.40	13.10	18.80	14.90	12.30	22.80	15.74
MCH	32.00	36.00	35.00	33.00	33.00	31.00	34.00	32.62
MCV	99.00	106.0	107.0	97.00	98.00	97.00	106.0	86.8
MCHC	32.00	34.00	33.00	34.00	34.00	32.00	32.00	34.3




**Figure (1):** Diagrammatic representation of the mean value of serum total bilirubin (mg/dl) in healthy and hyperbilirubinemic neonates groups.




**Figure (2):** Diagrammatic representation of the mean value (U/ gHb) of G6PD enzyme activity in healthy and hyperbilirubinemic neonates groups.







**Figure (3):** Diagrammatic representation of the mean value of TSH hormone concentration (Ulu/ml) in healthy and hyperbilirubinemic neonates groups.




**Figure (4):** Diagrammatic representation of the mean value of T<sub>4</sub> hormone concentration (ng/dl) in healthy and hyperbilirubinemic neonates groups.




**Figure (5):** Diagrammatic representation of the mean value of T<sub>3</sub> hormone concentration (ng/dl) in healthy and hyperbilirubinemic neonates groups.




**Figure (6):** Diagrammatic representation of the mean value of WBCs total count (cells/mm<sup>3</sup>) in healthy and hyperbilirubinemic neonates groups.




**Figure (7):** Diagrammatic representation of the mean value of RBCs and platelets counts (cells/mm<sup>3</sup>) in healthy and hyperbilirubinemic neonates groups.



**Figure (8):** Diagrammatic representation of the mean values % of hematocrit and reticulocytes (retics) in healthy and hyperbilirubinemic neonates groups.



**Figure (9):** Diagrammatic representation of the mean value of hemoglobin concentration (gm/dl) healthy and hyperbilirubinemic neonates groups.



**Figure (10):** Diagrammatic representation of the mean value of MCH, MCV and MCHC in healthy and hyperbilirubinemic neonates groups.